TLR7 (Toll Like Receptor 7)

Codon optimization and in silico cloning further ensured efficient expression in Escherichia coli, facilitating experimental application. These findings underscore the vaccine's promise as a therapeutic candidate against lung cancer, warranting further in vitro and in vivo investigations.

The pan-RAS mRNA vaccine demonstrates structural stability and strong immunogenic potential for PDAC. Synergistic immune activation with R848 may enhance anti-tumor efficacy, warranting experimental validation and toxicity assessment for clinical translation.

Drug-gene mapping revealed candidates spanning those already in clinical trials for HNC (e.g., Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, and Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing...HPV stratification enhances precision, literature-based validation strengthens confidence, and integrated drug mapping enables refinement of existing therapies and discovery of novel candidates for personalized treatment strategies. Code Availability: The full implementation of the GARD pipeline, including preprocessing scripts, statistical analysis modules, and visualization tools, is publicly available on GitHub.

Medications derived from ivy, thyme and Pelargonium extracts exhibit anti-inflammatory properties in a model mimicking viral infection in human lung epithelial cells.

Furthermore, we found chemical modulation of ETC complexes I and II activity can selectively alter PKM2-dependent signalling, enabling a fine-tuning of macrophage effector response. Given that TLR3 and TLR7 ligands are utilized as vaccine adjuvants and have demonstrated potential as cancer immunotherapies, our findings suggest that specific targeting of mitochondrial function can be used to manipulate macrophage responses and to improve the efficacy and limit the off-target effects of these therapeutics.

Together, these findings demonstrate that ECT differentially shapes DC survival and function depending on electric field intensity, with low-voltage ECT better preserving DC competence and higher voltages inducing activation but impairing responsiveness. These data highlight opportunities to optimise ECT protocols and rationally combine ECT with immune adjuvants to enhance therapeutic immunogenicity.

Additionally, single-cell RNA-sequencing demonstrates that Ehf expression is highly enriched in CCR7hi DCs in mice and humans. Our study thus reveals a conserved transcriptional program that regulates cDC maturation and immunosuppression.

Mechanistically, TLR7 regulated PD-L1 expression indirectly via cytokine signaling, rather than directly affecting PD-1 expression. These findings identify TLR7 as a key upstream modulator of immune checkpoint signaling during IAV infection and suggest that targeting TLR7, alone or with checkpoint inhibitors, may boost antiviral immunity and reduce T cell exhaustion.

TLR3, TLR7, TLR8, and TLR9 are all expressed in OL-no, OL-dys, and OSCC. Also, the study provides evidence for possible nucleocytoplasmic shuttling of TLRs.

This study investigated the individual and combinatorial effects of TLR3 Poly(I:C), TLR5 (Flagellin), and TLR7 (Imiquimod) ligands on nitric oxide (NO) production and pro-inflammatory cytokine expression in RAW 264.7 mouse macrophage cells...These findings highlight a potent crosstalk between TRIF-dependent (TLR3) and MyD88-dependent (TLR7, TLR5) signaling pathways, leading to amplified immune activation. Our study highlights the potential of synergistic TLR ligand combinations as powerful immunomodulators, offering promising avenues for the rational design of more effective vaccine adjuvants and innovative strategies in cancer immunotherapy.

Drug-gene mapping revealed candidates spanning already in clinical trials for HNC (e.g. Afatinib, Cabozantinib, Dasatinib, Brigatinib, Lenvatinib, Capivasertib, Erdafitinib) and emerging or repurposing candidates (Amuvatinib, XL765 (Voxtalisib), Golotimod, Artenimol, Quercetin, and Acetylsalicylic Acid), offering opportunities for precision repurposing...These included targeted therapies such as Fostamatinib, Nintedanib, Brigatinib, Regorafenib, and Lenvatinib, as well as emerging compounds like Artenimol, Quercetin, and Acetylsalicylic Acid (Aspirin). Through a combination of genomic analysis, network expansion, and literature validation, the GARD pipeline offers a powerful way to accelerate personalized cancer treatments while reducing cost and development time.

Consistently, R848-treated mice presented with mild white pulp atrophy and reduced antigen reactivity to the SFTSV nucleoprotein in the spleen. Collectively, modulation of TLR7 signaling, demonstrated by R848 activation and TLR7 deficiency, provides a novel approach to regulating antiviral immune responses against SFTSV infection.